Cover Image
市場調查報告書

東南亞的類風濕性關節炎治療藥市場 2022年

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

出版商 GBI Research 商品編碼 498257
出版日期 內容資訊 英文 140 Pages
訂單完成後即時交付
價格
Back to Top
東南亞的類風濕性關節炎治療藥市場 2022年 Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
出版日期: 2017年04月01日 內容資訊: 英文 140 Pages
簡介

東南亞 (韓國、新加坡、台灣、馬來西亞、菲律賓、泰國、越南,及印尼)的類風濕性關節炎治療藥市場,預計從2015年的10億4,000美元,到2022年達14億4,000萬美元,以4.7%的年複合成長率擴大。

本報告提供東南亞的類風濕性關節炎治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

  • 疾病的簡介
  • 流行病學
  • 症狀
  • 病因、病理學
  • 診斷
  • 預後
  • 治療指南、選項
  • 重感染、合併症

第3章 上市產品

  • 概要
  • 小分子緩解疾病性抗風濕藥
    • Methotrexate系產品
    • Xeljanz (tofacitinib) - Pfizer
  • 生物學性緩解疾病性抗風濕藥
    • Infliximab
    • Humira (adalimumab) - AbbVie
    • Etanercept
    • Rituximab
    • Orencia (abatacept) - Bristol-Myers Squibb
    • Simponi (golimumab) - Johnson & Johnson, Merck
    • Cimzia (certolizumab pegol) - UCB
    • Actemra (tocilizumab) - Roche
  • 上市產品的有效性和安全性比較

第4章 開發平台分析

  • 概要
  • 開發平台:各開發階段,分子類型,給藥途徑,計劃類型
  • 開發平台:各分子標的
  • 有前途的開發平台候補藥
    • Baricitinib - Eli Lilly
    • Sarilumab - Regeneron/Sanofi
    • Sirukumab - Johnson & Johnson
    • Peficitinib - Astellas
    • Upadacitinib - AbbVie
    • Filgotinib - Galapagos
  • 開發中產品的有效性和安全性比較
  • 產品競爭力架構

第5章 臨床實驗分析

  • 失敗率
    • 整體失敗率
    • 失敗率:各階段、分子類型
    • 失敗率:階段:各分子標的
  • 臨床實驗的期間
    • 臨床實驗期間:各開發階段、分子類型
    • 臨床實驗期間:各開發階段、分子標的
  • 臨床實驗的規模
    • 每一個產品的登記患者:各開發階段、分子類型/分子標的
    • 每一個臨床實驗登記患者:各開發階段、分子類型/分子標的
  • 臨床實驗標準的競爭分析

第6章 複數方案的預測

  • 各地區市場
  • 東南亞市場
  • 韓國
    • 治療藥的利用模式
    • 治療藥的年度成本
    • 市場規模
  • 新加坡
  • 台灣
  • 馬來西亞
  • 菲律賓
  • 泰國
  • 越南
  • 印尼
  • 市場動態

第7章 交易與策略性整合

  • 授權交易
  • 共同開發交易

第8章 附錄

目錄
Product Code: GBIHC438MR

Executive Summary

Rheumatoid arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years (Lefevre et al., 2009). Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability. RA can have a substantial impact on quality of life and place a considerable economic burden upon the patient.

The advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. The South-East Asia market, which for the purposes of this report comprises South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, is forecast to grow at a compound annual growth rate (CAGR) of 4.7%, from USD1.04 Billion in 2015 to USD1.44 Billion in 2022. South Korea accounted for most of the market in 2015 with a 29.9% share, followed by Malaysia with 19.0%, the Philippines with 14.2%, Vietnam with 9.4%, Taiwan with 8.5%, Indonesia with 7.1%, Singapore with 6.4%, and Thailand with 5.5%.

The entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Eli Lilly and Incyte's baricitinib, Regeneron's sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson's sirukumab, Astellas' peficitinib (ASP015K), and AbbVie's upadacitinib. Galapagos' filgotinib is in late-stage development, but it will not be launched during the forecast period, as its Phase III trial completion date is in Q3 2020.

The therapeutic market for RA has become extremely competitive owing to the number of new drug approvals. Competition for tumor necrosis factor alpha (TNF-α) inhibitors is particularly fierce and now dominates the treatment market for RA patients who are refractory to first-line DMARDs. In 2015, Humira (adalimumab), MabThera/Rituxan (rituximab) and Remicade (infliximab) were ranked among the top-10 best-selling drugs in the world, with global revenue of USD14.01 Billion, USD7.33 Billion and USD6.56 Billion, respectively, reflecting their groundbreaking clinical and commercial success.

The report "Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs" provides an introduction to rheumatoid arthritis (RA), covering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In addition, this report also provides the following analysis -

  • Provides an overview of the RA marketed products landscape, including product profiles of key marketed products and heat maps that compare the safety and efficacy parameters of the various drugs.
  • Analyzes the RA pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
  • Provides detailed analysis of recent clinical trials in RA by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the RA market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015-2022 period. The eight South-East Asia markets are covered and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for RA in South-East Asia markets.

Companies mentioned in this report: Eli Lilly and Incyte's baricitinib, Regeneron's sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson's sirukumab, Astellas' peficitinib (ASP015K), and AbbVie's upadacitinib. Galapagos' filgotinib

Scope

The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.

What are the competitive advantages of the existing novel drugs?

There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

Which classes of novel drugs are most prominent in the pipeline?

What is the potential for pipeline products to address unmet needs in the RA market?

Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.

How do failure rates vary by stage of development, molecule type, and molecular target?

How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.

Which markets make the most significant contribution to the current market size?

What are the epidemiology trends in these markets?

Will new market entrants lead to substantial changes in annual therapy costs?

How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.

Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

  • This report will enable you to -
  • Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
  • Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 8
  • 1.2 List of Figures 8

2 Introduction 10

  • 2.1 Disease Introduction 10
  • 2.2 Epidemiology 11
  • 2.3 Symptoms 11
  • 2.4 Etiology and Pathophysiology 11
  • 2.5 Diagnosis 13
    • 2.5.1 Physical Examination 13
    • 2.5.2 Blood Tests 13
    • 2.5.3 1987 Rheumatoid Arthritis Classification 14
    • 2.5.4 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 14
  • 2.6 Prognosis 14
  • 2.7 Treatment Guidelines and Options 15
    • 2.7.1 Pharmacological 16
    • 2.7.2 Methotrexate 16
    • 2.7.3 Hydroxychloroquine 17
    • 2.7.4 Leflunomide 17
    • 2.7.5 Sulfasalazine 17
    • 2.7.6 Cyclosporine 17
    • 2.7.7 Xeljanz (tofacitinib) 17
    • 2.7.8 Other Non-biologics 18
    • 2.7.9 Biologic Disease-Modifying Anti-rheumatic Drugs 18
    • 2.7.10 Disease Scoring Methods for Measuring Treatment Efficacy 19
  • 2.8 Co-infection or Co-morbidities 20

3 Marketed Products 21

  • 3.1 Overview 21
  • 3.2 Small-Molecule Disease-Modifying Anti-rheumatic Drugs 21
    • 3.2.1 Methotrexate-Based Products 21
    • 3.2.2 Xeljanz (tofacitinib) - Pfizer 22
  • 3.3 Biologic Disease-Modifying Anti-rheumatic Drugs 23
    • 3.3.1 Infliximab 23
    • 3.3.2 Humira (adalimumab) - AbbVie 24
    • 3.3.3 Etanercept 24
    • 3.3.4 Rituximab 25
    • 3.3.5 Orencia (abatacept) - Bristol-Myers Squibb 26
    • 3.3.6 Simponi (golimumab) - Johnson & Johnson, Merck 26
    • 3.3.7 Cimzia (certolizumab pegol) - UCB 27
    • 3.3.8 Actemra (tocilizumab) - Roche 27
  • 3.4 Comparative Efficacy and Safety of Marketed Products 28

4 Pipeline Analysis 34

  • 4.1 Overview 34
  • 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 34
  • 4.3 Pipeline by Molecular Target 36
  • 4.4 Promising Pipeline Candidates 39
    • 4.4.1 Baricitinib - Eli Lilly 39
    • 4.4.2 Sarilumab - Regeneron/Sanofi 41
    • 4.4.3 Sirukumab - Johnson & Johnson 43
    • 4.4.4 Peficitinib - Astellas 44
    • 4.4.5 Upadacitinib - AbbVie 46
    • 4.4.6 Filgotinib - Galapagos 47
  • 4.5 Comparative Efficacy and Safety of Pipeline Products 48
  • 4.6 Product Competitiveness Framework 50

5 Clinical Trial Analysis 52

  • 5.1 Failure Rate 52
    • 5.1.1 Overall Failure Rate 52
    • 5.1.2 Failure Rate by Phase and Molecule Type 54
    • 5.1.3 Failure Rate by Phase and Molecular Target 55
  • 5.2 Clinical Trial Duration 55
    • 5.2.1 Trial Duration by Stage of Development and Molecule Type 55
    • 5.2.2 Trial Duration by Stage of Development and Molecular Target 56
  • 5.3 Clinical Trial Size 57
    • 5.3.1 Patient Enrollment per Product by Stage of Development and Molecule Type/Molecular Target 57
    • 5.3.2 Patient Enrollment per Trial by Stage of Development and Molecule Type/Molecular Target 59
  • 5.4 Summary of Clinical Trial Metrics 61

6 Multi-Scenario Forecast 63

  • 6.1 Geographical Markets 63
  • 6.2 South-East Asia Markets 63
  • 6.3 South Korea 66
    • 6.3.1 Treatment Usage Patterns 66
    • 6.3.2 Annual Cost of Therapy 66
    • 6.3.3 Market Size 67
  • 6.4 Singapore 68
    • 6.4.1 Treatment Usage Patterns 68
    • 6.4.2 Annual Cost of Therapy 69
    • 6.4.3 Market Size 69
  • 6.5 Taiwan 70
    • 6.5.1 Treatment Usage Patterns 70
    • 6.5.2 Annual Cost of Therapy 71
    • 6.5.3 Market Size 72
  • 6.6 Malaysia 73
    • 6.6.1 Treatment Usage Patterns 73
    • 6.6.2 Annual Cost of Therapy 74
    • 6.6.3 Market Size 75
  • 6.7 Philippines 76
    • 6.7.1 Treatment Usage Patterns 76
    • 6.7.2 Annual Cost of Therapy 77
    • 6.7.3 Market Size 78
  • 6.8 Thailand 79
    • 6.8.1 Treatment Usage Patterns 79
    • 6.8.2 Annual Cost of Therapy 80
    • 6.8.3 Market Size 81
  • 6.9 Vietnam 82
    • 6.9.1 Treatment Usage Patterns 82
    • 6.9.2 Annual Cost of Therapy 83
    • 6.9.3 Market Size 84
  • 6.10 Indonesia 85
    • 6.10.1 Treatment Usage Patterns 85
    • 6.10.2 Annual Cost of Therapy 86
    • 6.10.3 Market Size 87
  • 6.11 Market Dynamics (Drivers and Barriers) 88
    • 6.11.1 Drivers 88
    • 6.11.2 Barriers 89

7 Deals and Strategic Consolidations 90

  • 7.1 Licensing Deals 90
    • 7.1.1 Deals by Region and Value 90
    • 7.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 92
    • 7.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target 92
    • 7.1.4 Mylan Enters into Licensing Agreement with Momenta Pharmaceuticals for Biosimilar Candidates 95
    • 7.1.5 Roche Enters into Licensing Agreement with Proximagen for VAP-1 Inhibitor 95
    • 7.1.6 Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab 96
    • 7.1.7 Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-0061 96
  • 7.2 Co-development 97
    • 7.2.1 Deals by Region and Value 97
    • 7.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 98
    • 7.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 99
    • 7.2.4 Gilead Sciences Enters into Co-development Agreement with Galapagos 102
    • 7.2.5 Nextera Enters into Research Agreement with Janssen Biotech 103
    • 7.2.6 GlaxoSmithKline Enters into Global Agreement with Archemix 103
    • 7.2.7 Chroma Therapeutics Enters into Co-development Agreement with GlaxoSmithKline 103

8 Appendix 105

  • 8.1 All Pipeline Drugs by Stage of Development 105
    • 8.1.1 Discovery 105
    • 8.1.2 Preclinical 108
    • 8.1.3 IND/CTA-filed 117
    • 8.1.4 Phase I 118
    • 8.1.5 Phase II 120
    • 8.1.6 Phase III 122
    • 8.1.7 Pre-registration 123
  • 8.2 Summary of Multi-Scenario Market Forecasts to 2022 123
  • 8.3 Abbreviations 127
  • 8.4 References 129
  • 8.5 Research Methodology 136
    • 8.5.1 Secondary Research 137
    • 8.5.2 Marketed Product Profiles 137
    • 8.5.3 Late-Stage Pipeline Candidates 137
    • 8.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products 137
    • 8.5.5 Pipeline Analysis 138
    • 8.5.6 Forecasting Model 139
    • 8.5.7 Deals Data Analysis 140
  • 8.6 Contact Us 140
  • 8.7 Disclaimer 140

List of Tables

  • Table 1: RA Therapeutics Market, South-East Asia, Prevalence rate (%), 2015 11
  • Table 2: ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010 14
  • Table 3: RA Therapeutics Market, Global, Licensing Deals Valued over $10m, 2006-2016 96
  • Table 4: RA Therapeutics Market, Global, Co-development Deals Valued over $10m, 2006-2016 103
  • Table 5: RA Therapeutics Market, Global, All Pipeline Products, Discovery, 2016 105
  • Table 6: RA Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016 108
  • Table 7: RA Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016 117
  • Table 8: RA Therapeutics Market, Global, All Pipeline Products, Phase I, 2016 118
  • Table 9: RA Therapeutics Market, Global, All Pipeline Products, Phase II, 2016 120
  • Table 10: RA Therapeutics Market, Global, All Pipeline Products, Phase III, 2016 122
  • Table 11: RA Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016 123
  • Table 12: RA Therapeutics Market, South-East Asia, Market Forecast, 2015-2022 123
  • Table 13: RA Therapeutics Market, South Korea, Market Forecast, 2015-2022 124
  • Table 14: RA Therapeutics Market, Singapore, Market Forecast, 2015-2022 124
  • Table 15: RA Therapeutics Market, Taiwan, Market Forecast, 2015-2022 124
  • Table 16: RA Therapeutics Market, Malaysia, Market Forecast, 2015-2022 125
  • Table 17: RA Therapeutics Market, Philippines, Market Forecast, 2015-2022 125
  • Table 18: RA Therapeutics Market, Thailand, Market Forecast, 2015-2022 125
  • Table 19: RA Therapeutics Market, Vietnam, Market Forecast, 2015-2022 126
  • Table 20: RA Therapeutics Market, Indonesia, Market Forecast, 2015-2022 126

List of Figures

  • Figure 1: American College of Rheumatology Treatment Guidelines, 2012 16
  • Figure 2: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Synthetic Disease Modifying Anti-rheumatic Marketed Products 30
  • Figure 3: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for TNF-α Biologic Disease Modifying Anti-rheumatic Marketed Products 31
  • Figure 4: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Non TNF-α Biologic Disease Modifying Anti-rheumatic Marketed Products 32
  • Figure 5: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Targeted Synthetic Disease Modifying Anti-rheumatic Marketed Products 33
  • Figure 6: RA Therapeutics Market, Global, Pipeline, 2016 35
  • Figure 7 RA Therapeutics Market, Global, Pipeline by Molecular Target, 2016 38
  • Figure 8: RA Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 39
  • Figure 9: RA Therapeutics Market, South-East Asia, Baricitinib Forecast ($m), 2017-2022 41
  • Figure 10: RA Therapeutics Market, South-East Asia, Sarilumab Forecast ($m), 2018-2022 42
  • Figure 11: RA Therapeutics Market, South-East Asia, Sirukumab Forecast ($m), 2018-2022 44
  • Figure 12: RA Therapeutics Market, South-East Asia, Peficitinib Forecast ($m), 2020-2022 46
  • Figure 13: RA Therapeutics Market, South-East Asia, Upadacitinib Forecast ($m), 2020-2022 47
  • Figure 14: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 49
  • Figure 15: RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2016 51
  • Figure 16: RA Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2016 53
  • Figure 17: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2016 54
  • Figure 18: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2016 55
  • Figure 19: RA Therapeutics Market, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2016 56
  • Figure 20: RA Therapeutics Market, Global, Clinical Trial Duration by Molecular Target, 2006-2016 57
  • Figure 21: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2006-2016 58
  • Figure 22: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006-2016 59
  • Figure 23: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2016 60
  • Figure 24: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2016 61
  • Figure 25: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type 61
  • Figure 26: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target 62
  • Figure 27: RA Therapeutics Market, South-East Asia, Treatment Usage Patterns (million), 2015-2022 64
  • Figure 28: RA Therapeutics Market, South-East Asia, Market Size ($bn), 2015-2022 65
  • Figure 29: RA Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2015-2022 66
  • Figure 30: RA Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022 67
  • Figure 31: RA Therapeutics Market, South Korea, Market Size ($m), 2015-2022 68
  • Figure 32: RA Therapeutics Market, Singapore, Treatment Usage Patterns ('000), 2015-2022 68
  • Figure 33: RA Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015-2022 69
  • Figure 34: RA Therapeutics Market, Singapore, Market Size ($m), 2015-2022 70
  • Figure 35: RA Therapeutics Market, Taiwan, Treatment Usage Patterns ('000), 2015-2022 71
  • Figure 36: RA Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015-2022 72
  • Figure 37: RA Therapeutics Market, Taiwan, Market Size ($m), 2015-2022 73
  • Figure 38: RA Therapeutics Market, Malaysia, Treatment Usage Patterns (million), 2015-2022 74
  • Figure 39: RA Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015-2022 75
  • Figure 40: RA Therapeutics Market, Malaysia, Market Size ($m), 2015-2022 76
  • Figure 41: RA Therapeutics Market, Philippines, Treatment Usage Patterns (million), 2015-2022 77
  • Figure 42: RA Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015-2022 78
  • Figure 43: RA Therapeutics Market, Philippines, Market Size ($m), 2015-2022 79
  • Figure 44: RA Therapeutics Market, Thailand, Treatment Usage Patterns ('000), 2015-2022 80
  • Figure 45: RA Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015-2022 81
  • Figure 46: RA Therapeutics Market, Thailand, Market Size ($m), 2015-2022 82
  • Figure 47: RA Therapeutics Market, Vietnam, Treatment Usage Patterns (million), 2015-2022 83
  • Figure 48: RA Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015-2022 84
  • Figure 49: RA Therapeutics Market, Vietnam, Market Size ($m), 2015-2022 85
  • Figure 50: RA Therapeutics Market, Indonesia, Treatment Usage Patterns (million), 2015-2022 86
  • Figure 51: RA Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015-2022 87
  • Figure 52: RA Therapeutics Market, Indonesia, Market Size ($m), 2015-2022 88
  • Figure 53: RA Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016 91
  • Figure 54: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 92
  • Figure 55: RA Therapeutics Market, Global, Licensing Deals by Stage of Development, and Deal Value, 2006-2016 93
  • Figure 56: RA Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016 94
  • Figure 57: RA Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2016 95
  • Figure 58: RA Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016 98
  • Figure 59: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016 99
  • Figure 60: RA Therapeutics Market, Global, Co-development Deals by Stage of Development, and Deal Value, 2006-2016 100
  • Figure 61: RA Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2016 101
  • Figure 62: Rheumatoid Arthritis Market, Global, Co-development Deals by Molecular Target, 2006-2016 102
Back to Top